Phase II Trial of Sorafenib as Second Line Therapy in Patients With Advanced or Metastatic Gastric Cancer
Up to now, although FU based, cisplatin based and taxane based regimen, and ECF regimen have
been suggested as the first line therapy for A/MGC by FDA, there is no standard regimen for
patients with A/MGC as second line treatment. Based on the promising results of sorafenib in
primary hepatic carcinoma and renal cancer, we design this clinical trial to evaluate the
efficacy, time to progression and overall survival of sorafenib for A/MGC patients as a
second line treatment.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
time to progression
every six weeks
Jin Li, PhD, M.D.
China: Ethics Committee